Tag : NON-RELAPSING SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

CONFERENCE UPDATE

Tolebrutinib slows disability progression in nrSPMS: Results from the phase 3 HERCULES trial
The phase 3 HERCULES trial demonstrates that tolebrutinib reduces disability progression in non-relapsing secondary progressive multiple sclerosis (nrSPMS) by 31%, offering hope for this underserved population.